Kones, Richard J.; Dombeck, David H.; Phillips, John H.
October 1972
Angiology;Oct1972, Vol. 23 Issue 9, p525
Academic Journal
Twelve patients with cardiogenic shock were given a continuous intravenous infusion of glucagon at a rate of 3 mg/hour. Four patients with an acute myocardial infarction occurring as their first clinical manifestation of heart disease survived. All eight who died had heart diseases of long duration prior to the onset of cardiogenic shock. As would be expected, increased urine output, stable restored blood pressures, and decreased central venous pressures indicated a more favorable prognosis. Hypokalemia, hypocalcemia, and hyperglycemia were consequences of extracardiac metabolic actions of glucagon. Suppression of premature ventricular complexes reflected an antiarrhythmic property of glucagon. More intense and frequent chest pain (two patients) and depressed ST segments on ECG (one patient) during glucagon therapy was noted. Since glucagon is considered a secondary coronary vasodilator, these observations suggest further experience is necessary. Glucagon may be of greater benefit in cardiogenic shock when clinical heart diseases of long duration did not precede the onset of the shock syndrome. More investigation with this agent appears warranted.


Related Articles

  • Exercise Helps Heart Attack Patients Who Are Depressed, Without Social Support.  // Ascribe Newswire: Medicine;5/4/2004, p113 

    Heart attack patients who are depressed or without social support are more than twice as likely to die of a second heart attack if they do not exercise, according the results of a large-scale national trial led by Duke University Medical Center researchers. The study, which followed 2,078...

  • THE ASCOT AFTERMATH WHAT GPS NEED TO KNOW.  // Pulse;10/8/2005, Vol. 65 Issue 39, p44 

    Reports that Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) results published has plunged hypertension management into turmoil. Announcement on the revision of Anglo-Scandinavian Cardiac Outcomes Trial's guidance; Reduction on the primary endpoint of non-fatal myocardial infarction and fatal...

  • Late Stent Thrombosis Following Implantation of a Drug Eluting Stent Presenting as Acute Myocardial Infarction: A Case Report. Chandra, K. Sarat; Kumar, Ritesh // Internet Journal of Cardiology;2007, Vol. 4 Issue 1, p7 

    Drug eluting stents (DES) have made a great impact on the practice of interventional cardiology and a wide range of coronary lesions are being subjected to angioplasty with drug eluting stents. One important problem encountered with their use is late stent thrombosis. We herein report a case...

  • Primary Percutaneous Coronary Intervention.  // Current Medical Literature: Cardiology;2007, Vol. 26 Issue 2, p56 

    The article presents editor's notes on research about primary percutaneous coronary intervention (PPCI). A prospective study by B. R. Brodie identifies cardiogenic shock in some patients who were enrolled in a registry and underwent PPCI between 1984 and 2004. Another research by P. X. Adams...

  • Coronary Artery Disease -- Myocardial Infarction.  // Current Medical Literature: Interventional Cardiology Monitor;2005, Vol. 12 Issue 4, p99 

    The article presents information about several papers related to myocardial infarction, a coronary artery disease. The article titled "Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty,"...

  • Full Coverage for Preventive Medications after Myocardial Infarction. Choudhry, Niteesh K.; Avorn, Jerry; Glynn, Robert J.; Antman, Elliott M.; Schneeweiss, Sebastian; Toscano, Michele; Reisman, Lonny; Fernandes, Joaquim; Spettell, Claire; Lee, Joy L.; Levin, Raisa; Brennan, Troyen; Shrank, William H. // New England Journal of Medicine;12/1/2011, Vol. 365 Issue 22, p2088 

    Background: Adherence to medications that are prescribed after myocardial infarction is poor. Eliminating out-of-pocket costs may increase adherence and improve outcomes. Methods: We enrolled patients discharged after myocardial infarction and randomly assigned their insurance-plan sponsors to...

  • Coronary microembolization does not induce acute preconditioning against infarction in pigs–the role of adenosine. Skyschally, Andreas; Schulz, Rainer; Gres, Petra; Konietzka, Ina; Martin, Claus; Haude, Michael; Erbel, Raimund; Heusch, Gerd // Cardiovascular Research;Aug2004, Vol. 63 Issue 2, p313 

    Objective: After coronary microembolization (ME) adenosine is released from ischemic areas of the microembolized myocardium. This adenosine dilates vessels in adjacent nonembolized myocardium and increases coronary blood flow. For ischemic preconditioning (IP) to protect the myocardium against...

  • Unprotected Left Main Coronary Artery Intervention. Abuzahra, Mohammed M.; Mesa, Andres; Treistman, Bernardo // Texas Heart Institute Journal;2007, Vol. 34 Issue 4, p479 

    Medical therapy alone often insufficiently alters the clinical course of patients who have experienced acute myocardial infarction and concomitant cardiogenic shock, and in whom the left main coronary artery is the culprit vessel. Emergency coronary artery bypass grafting is an effective yet...

  • Patient-reported outcomes as predictors of 10-year survival in women after acute myocardial infarction. Norekvål, Tone M.; Fridlund, Bengt; Rokne, Berit; Segadal, Leidulf; Wentzel-Larsen, Tore; Nordrehaug, Jan Erik // Health & Quality of Life Outcomes;2010, Vol. 8, p140 

    Background: Patient-reported outcomes are increasingly seen as complementary to biomedical measures. However, their prognostic importance has yet to be established, particularly in female long-term myocardial infarction (MI) survivors. We aimed to determine whether 10-year survival in older...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics